Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide

Patent metadata

Field	Value
Publication number	US-11970522-B2
Application number	US-202017006219-A
Country	US
Kind code	B2
Filing date	Aug 28, 2020
Priority date	Nov 9, 2015
Publication date	Apr 30, 2024
Grant date	Apr 30, 2024

Abstract

The disclosure pertains to epitopes identified in A-beta including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.

First claim

The invention claimed is:

1. A cyclic compound comprising: an A-beta peptide and a linker, wherein the A-beta peptide consists of QKLV (SEQ ID NO: 1), and wherein the linker is covalently coupled to the A-beta peptide N-terminus residue and the A-beta C-terminus residue, wherein the linker consists of amino acids GCG or CGC.

2. The cyclic compound of claim 1 , wherein the linker consists of amino acids GCG.

3. The cyclic compound of claim 1 , wherein the linker consists of amino acids CGC.

4. The cyclic compound of claim 1 , wherein the cyclic compound consists of the sequence CGQKLVG (SEQ ID NO: 3).

5. An isolated cyclic peptide comprising an A-beta peptide and a linker, wherein the A-beta peptide consists of the sequence of QKLV (SEQ ID NO: 1), wherein the linker is covalently coupled to the A-beta peptide N-terminus residue and the A-beta C-terminus residue, and wherein the linker consists of amino acids GCG or CGC.

6. An immunogen comprising the cyclic compound of claim 1 .

7. The immunogen of claim 6 , wherein the cyclic compound is coupled to bovine serum albumin (BSA) or keyhole limpet haemocyanin (KLH).

8. An immunogen comprising the cyclic compound of claim 4 and an immunogenicity-enhancing agent, wherein the immunogenicity-enhancing agent is Keyhole Limpet Hemocyanin (KLH).

9. An immunogen comprising the cyclic peptide of claim 4 .

10. A composition comprising the cyclic compound of claim 1 or an immunogen comprising the cyclic compound.

11. The composition of claim 10 , further comprising an adjuvant.

12. The composition of claim 11 , wherein the adjuvant is an alum adjuvant or polyphosphazene.

13. The composition of claim 12 , wherein the alum adjuvant is aluminum hydroxide or aluminum phosphate.

14. A kit comprising the cyclic compound of claim 1 or an immunogen comprising the cyclic compound of claim 1 .

15. A method of inducing an immune response in a subject, comprising administering to the subject an immunogen comprising the compound of claim 1 , and/or a composition comprising the compound or the immunogen.

16. The method of claim 15 , wherein the method further comprises isolating cells and/or antibodies that specifically or selectively bind the A-beta peptides of the compound or immunogen administered.

Assignees

• Univ British Columbia

Inventors

• Cashman Neil R
• Plotkin Steven S

Classifications

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• C07K14/4711 Primary

  Alzheimer's disease; Amyloid plaque core protein · CPC title

• A61K39/0008

  Antigens related to auto-immune diseases; Preparations to induce self-tolerance · CPC title

• A61K47/643

  Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL] · CPC title

• A61K47/646

  the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines · CPC title